Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer

References

• ANTONI S, FERLAY J, SOERJOMATARAM I, et al. Bladder cancer incidence and mortality: a global overview and recent trends [J]. European Urology. 2017;71(1):96–108.
   Google Scholar
• SAGINALA K, BARSOUK A, ALURU J, et al. Epidemiology of bladder cancer [J]. John Wiley & Sons, Inc. 2020;5(4):1.
   Google Scholar
• SIEGEL R, Miller K. JEMAL A J C A C J F C. Cancer Stat. 2020;70(1): 7–30. 2020 [J].
   Google Scholar
• DEL BENE G, CALABRò F, Giannarelli D, et al. Neoadjuvant vs. adjuvant chemotherapy in muscle invasive bladder cancer (MIBC): Analysis from the RISC database [J]. Front Oncol. 2018;8:463.
   Google Scholar
• Keck B, WACH S, Taubert H, et al. Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients [J]. International Journal of Cancer.2015;136(2):443–451.
   Google Scholar
• Sanford T, MENG M, RAILKAR R, et al. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma [J]. Clinical Epigenetics. 2018; 10(1):19.
   Google Scholar
• Lei A, CHENG L, Pan CJEROAT. Current treatment of metastatic bladder cancer and future directions [J]. Expert Review of Anticancer Therapy. 2011;11(12):1851–1862.
   Google Scholar
• GRIVAS P, AGARWAL N, Pal S, et al. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice [J]. Cancer Treatment Reviews. 2021;97:102187.
   Google Scholar
• Aurilio G, CIMADAMORE A, LOPEZ-BELTRAN A, et al. Narrative review: update on immunotherapy and pathological features in patients with bladder cancer [J]. Translational Andrology and Urology. 2021;10(3):1521–1529.
   Google Scholar
• Li X, LUO L, JIANG M, et al. Cocktail strategy for ‘cold’ tumors therapy via active recruitment of CD8+ T cells and enhancing their function [J]. Journal of Controlled Release. 2021;334:413–426.
   Google Scholar
• LIU Y. SUN Z J T. Turning cold tumors into hot tumors by improving T-cell infiltration [J]. Theranostics. 2021;11(11):5365–5386.
   Google Scholar
• BAI X, MORAES T. REITHMEIER R J M M B. Structural biology of solute carrier (SLC) membrane transport proteins [J]. Mol Membr Biol.2017;34:1–32 .
   Google Scholar
• GARIBSINGH R. SCHLESSINGER A J T I P S. advances and challenges in rational drug design for SLCs [J]. Trends Pharmacol Sci. 2019;40(10):790–800.
   Google Scholar
• Li Q, SHU YJM, Therapies C. Role of solute carriers in response to anticancer drugs [J]. Molecular & Cellular Therapies. 2014;2(1):15.
   Google Scholar
• SAITO Y, Li L, Coyaud E, et al. LLGL2 rescues nutrient stress by promoting leucine uptake in ER breast cancer [J]. Nature. 2019;569(7755):275–279.
   Google Scholar
• SHEN L, QIAN C, CAO H, et al. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma [J]. World J Surg Oncol. 2018;16(1):235.
   Google Scholar
• GROZIO A, Mills K, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter [J]. Nat Metab. 2019;1(1):47–57.
   Google Scholar
• FANGNING W, Chunguang M, Hailiang Z, et al. Identification and validation of soluble carrier family expression signature for predicting poor outcome of renal cell carcinoma [J]. J Cancer. 2017;8(11):2010–2017.
   Google Scholar
• Wang L, ZHANG Q, Wu P, et al. SLC12A5 interacts and enhances SOX18 activity to promote bladder urothelial carcinoma progression via upregulating MMP7 [J]. Cancer Sci. 2020;111(7):2349–2360.
   Google Scholar
• ZHANG L, Li L, Zhan Y, et al. Identification of immune-related lncRNA signature to predict prognosis and immunotherapeutic efficiency in bladder cancer [J]. Front Oncol. 2020;10:542140.
   Google Scholar
• HU J, ZHOU L, Song Z, et al. The identification of new biomarkers for bladder cancer: a study based on TCGA and GEO datasets [J]. Journal of Cellular Physiology. 2019;234(9):15607–15618.
   Web of Science ®Google Scholar
• Chen S, ZHANG N, SHAO J, et al. A novel gene signature combination improves the prediction of overall survival in urinary bladder cancer [J]. Journal of Cancer. 2019;10(23):5744–5753.
   Google Scholar
• Chen M, ZHANG S, Wen X, et al. Prognostic value of CLIC3 mRNA overexpression in bladder cancer [J]. PeerJ. 2020;8:e8348.
   Google Scholar
• Xu Y, Wu G, Li J, et al. Screening and identification of key biomarkers for bladder cancer: a study based on TCGA and GEO data [J]. BioMed Research International. 2020;2020:1–20.
   Google Scholar
• Xu H, XIONG C, Chen Y, et al. Identification of rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma [J]. Bioengineered. 2021;12(1):2664–2675.
   Google Scholar
• Sang L, Sun L, Wang A, et al. The N6-methyladenosine features of mRNA and aberrant expression of m6A modified genes in gastric cancer and their potential impact on the risk and prognosis [J]. Front Genet. 2020;11:561566.
   Google Scholar
• LIU S, He L, SHENG C, et al. Overexpression of RIPK4 predicts poor prognosis and promotes metastasis in ovarian cancer [J].BioMed Research International. 2021; 2021(6):1–11.
   Google Scholar
• Arab A, KARIMIPOOR M, Irani S, et al. Potential circulating miRNA signature for early detection of NSCLC [J]. Cancer Genetics. 2017:150-158.
   Google Scholar
• Song Y, Huang R, Wu S, et al. Diagnostic and prognostic role of NR3C4 in breast cancer through a genomic network understanding [J]. Pathol Res Pract. 2021;217: 153310.
   Google Scholar
• LIU Y, Wu Y, ZHANG P, et al. CXCL12 and CD3E as Indicators for tumor microenvironment modulation in bladder cancer and their correlations with immune infiltration and molecular subtypes [J]. Front Oncol. 2021;11:636870.
   Google Scholar
• XUE G, HUA L, ZHOU N, et al. Characteristics of immune cell infiltration and associated diagnostic biomarkers in ulcerative colitis: results from bioinformatics analysis [J]. Bioengineered. 2021;12(1):252–265.
   Google Scholar
• Li T, FU J, ZENG Z, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells [J]. Nucleic Acids Res. 2020;48:W509–W14.
   Google Scholar
• Xu F, SHEN J, Xu SJFIC, et al. Integrated bioinformatical analysis identifies GIMAP4 as an immune-related prognostic biomarker associated with remodeling in cervical cancer tumor microenvironment [J]. Frontiers in Cell and Developmental Biology. 2021; 9:637400.
   Google Scholar
• Wang L, Wang P, SU X, et al. Circ_0001658 promotes the proliferation and metastasis of osteosarcoma cells via regulating miR-382-5p/YB-1 axis [J]. Cell Biochemistry and Function. 2020;38(1):77–86.
   Google Scholar
• DEVELOPMENT, SMOLENSKY D, RATHORE K, CEKANOVA MJDD, et al. Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer [J]. Drug Design Development & Therapy. 2016;10:3305–3322.
   Google Scholar
• Wang L, LEITE DE OLIVEIRA R, HUIJBERTS S, et al. An acquired vulnerability of drug-resistant melanoma with therapeutic potential [J]. Cell. 2018;173:1413–1425.e14.
   Google Scholar
• Sprowl J, MIKKELSEN T, GIOVINAZZO H, et al. Contribution of tumoral and host solute carriers to clinical drug response [J]. Drug Resist Updat. 2012;15(1-2):5-20.
   Google Scholar
• Cervenkova L, VYCITAL O, BRUHA J, et al. Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma [J]. Sci Rep.2019;9:19782. .
   Google Scholar
• Sutherland R, MEESON A. LOWES S J C M R. Solute transporters and malignancy: establishing the role of uptake transporters in breast cancer and breast cancer metastasis [J]. Cancer Metastasis Rev. 2020;39(3):919–932.
   Google Scholar
• ANSARI R, Craze M, Althobiti M, et al. Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer [J]. Br J Cancer. 2020;122(1):94–101.
   Google Scholar
• Song W, Li D, Tao L, et al. Solute carrier transporters: the metabolic gatekeepers of immune cells [J]. Acta Pharmaceutica Sinica B. 2020;10(1):61–78.
   Google Scholar
• MORIOKA S, Perry J, Raymond M, et al. Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release [J]. Nature. 2018;563:714–718.
   Google Scholar
• ZHANG Y, ZHANG Y, Sun K, et al. The SLC transporter in nutrient and metabolic sensing, regulation, and drug development [J]. J Mol Cell Biol. 2019;11(1):1–13.
   Google Scholar
• Lin L, YEE S, Kim R, et al. SLC transporters as therapeutic targets: emerging opportunities [J]. Nature Reviews Drug Discovery. 2015;14(8):543–560.
   Google Scholar
• Ma Y, Chen Y, Li Y, et al. Cystatin A suppresses tumor cell growth through inhibiting epithelial to mesenchymal transition in human lung cancer [J]. Oncotarget. 2018;9(18):14084–14098.
   Google Scholar
• John Mary D, SIKARWAR G, KUMAR A, et al. Interplay of ERα binding and DNA methylation in the intron-2 determines the expression and estrogen regulation of cystatin A in breast cancer cells [J]. Molecular and Cellular Endocrinology. 2020;504:110701.
   Google Scholar
• KOMURA T, TAKABATAKE H, HARADA K, et al. Clinical features of cystatin A expression in patients with pancreatic ductal adenocarcinoma [J].Cancer Sci. 2017;108(11):2122–2129.
   Google Scholar
• Cai Y, Li J, Lu A, et al. Increased serum levels of macrophage inflammatory protein-3α and cystatin a predict a poor prognosis of nasopharyngeal carcinoma [J]. Medicine. 2014;93(22):e123.
   Google Scholar
• Butler M, FUKUI T, SALIT J, et al. Modulation of cystatin A expression in human airway epithelium related to genotype, smoking, COPD, and lung cancer [J]. Cancer Research. 2011;71(7):2572–2581.
   Google Scholar
• AUGUSTIN R, DELGOFFE G, NAJJAR YJC. Characteristics of the tumor microenvironment that influence immune cell functions: Hypoxia, oxidative stress, metabolic alterations [J]. Cancers. 12(12):2020.
   Google Scholar
• Lyu Q, Lin A, CAO M, et al. Alterations in TP53 are a potential biomarker of bladder cancer patients who benefit from immune checkpoint inhibition [J]. Cancer control: journal of the Moffitt Cancer Center. 2020;27(1):1073274820976665.
   Google Scholar
• LOPEZ-BELTRAN A, CIMADAMORE A, Blanca A, et al. Immune checkpoint inhibitors for the treatment of bladder cancer [J].Cancers. 2021; 13(1).
   Google Scholar
• SZABADOS B, PRENDERGAST A, Jackson-spence F, et al. Immune checkpoint inhibitors in front-line therapy for urothelial cancer [J]. Eur Urol Oncol. 2021;30:S2588-9311(21)00044-4.
   Google Scholar
• YANG H, Wu C, Chen J, et al. Treatment strategies and metabolic pathway regulation in urothelial cell carcinoma: a comprehensive review [J].Int J Mol Sci. 2020;21(23):8993.
   Google Scholar
• NISAR S, YOUSUF P, MASOODI T, et al. Chemokine-cytokine networks in the head and neck tumor microenvironment [J]. International Journal of Molecular Sciences. 2021;22(9)(4584):1–23.
   Google Scholar
• STURM G, FINOTELLO F, PETITPREZ F, et al. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology [J]. Bioinformatics.2019;35(14):i436–i445.
   Google Scholar